IAG to Attend Biotech Week of Meetings in San Francisco, USA, 12-15 January 2020

News

IAG to Attend Biotech Week of Meetings in San Francisco, USA, 12-15 January 2020

IAGs’ bio-partnering and management team will be attending biotech week in San Francisco.  IAG’s CEO, Dr. Olga Kubassova will attend JP Morgan meeting and Bio-Partnering Director and Head of Therapeutic Innovation, Dr. Diana Roettger will be attending Biotech Showcase and satellite events in San Francisco, USA, from January 12-15, 2020.

‘We see an increasing demand for an expert driven targeted development strategy, that often brings together smart use of technology, advanced imaging and AI. This de-risks biotech investors risks and increases changes of success, especially in early efficacy studies,’ said Dr. Diana Roettger of IAG.

Bio-Partnering is an independent investment division of IAG. We are building a diversified investment portfolio of innovative life science companies at various stages of clinical development. By bringing strategic collaborators and smart investments, we support their drug development efforts through clinical trials to market entry.
Our biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, immunology markets.

‘Our Bio-Partnering team has signed 6 successful partnerships with blue-chip pharma companies, public and private biotechnology players in 2019. We are excited to start 2020 and look forward to attending biotech week in San Francisco’, added Dr. Olga Kubassova, CEO of IAG.

About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News

IAG’s Team is Presenting on AI Driven DCE-MRI Analysis in Rheumatology

Prof. Boesen will speak at the European Society of Musculoskeletal Radiology.

Meet IAG at the International Workshop on Osteoarthritis Imaging’21

Dr. Olga Kubassova, CEO and Prof. Mikael Boesen of IAG will speak at IWOAI.

IAG and Collaborators Will Present at ASCO, June 4-8, 2021

Detailing integrated use of AI and CT / MRI in clinical trials.

IAG’s CEO Speaks to the Science Advisory Board

How computational analysis is improving clinical trial imaging and efficacy data.

Events